Clinicopathological impact of VEGFR2 and VEGF‐C in patients with EGFR ‐major mutant NSCLC receiving osimertinib

BACKGROUND: Vascular endothelial growth factor (VEGF) has been identified as one of the resistant mechanisms to epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs). However, the relationship between the efficacy of osimertinib and protein expression of VEGF family members in pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaira, Kyoichi, Imai, Hisao, Mouri, Atsuto, Hashimoto, Kosuke, Miura, Yu, Shiono, Ayako, Yamaguchi, Ou, Kobayashi, Kunihiko, Kawasaki, Tomonori, Yasuda, Masanori, Kagamu, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10569903/
https://www.ncbi.nlm.nih.gov/pubmed/37605832
http://dx.doi.org/10.1111/1759-7714.15082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10569903/
https://www.ncbi.nlm.nih.gov/pubmed/37605832
http://dx.doi.org/10.1111/1759-7714.15082

Ejemplares similares